drugset / Trial / NCT00947375

Lamictal TM, Haloperidol Decanoate in Schizophrenia

NCT00947375

Phase 4 Terminated 335 enrolled Central Mental Clinic for Outpatients of Baku City
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the effect of lamotrigine augmentation of Haloperidol decanoate in the treatment of Resistant Schizophrenia predominantly by verbal resistant hallucinosis: A randomized, double-blind, placebo-controlled, study. Nadir A.Aliyev \& Zafar N.Aliyev Central Mental Clinic for Outpatients of Baku city of Azerbaijan Republic Abstract: OBJECTIVE: The current paper reports on a double-blind, randomized study of the role of lamotrigine as an augmentation agent to haloperidol decanoate in the treatment of out patient's schizophrenia with verbal resistant hallucinosis.

Timeline

Start
2005-01
Primary completion
2006-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamotrigine Small molecule 150 mg Oral
Subject Lamotrigine Small molecule 200 mg Oral
Background Haloperidol Decanoate Small molecule 50 mg Intramuscular

Indications